Edition:
India

Alpine Immune Sciences Inc (ALPN.OQ)

ALPN.OQ on NASDAQ Stock Exchange Global Market

9.80USD
10 Jul 2020
Change (% chg)

$0.34 (+3.59%)
Prev Close
$9.46
Open
$9.31
Day's High
$9.83
Day's Low
$9.16
Volume
18,417
Avg. Vol
144,855
52-wk High
$15.00
52-wk Low
$2.09

Select another date:

Thu, Jul 9 2020

BRIEF-Alpine Immune Sciences Inc Files For Mixed Shelf Of Up To $60 Mln

* ALPINE IMMUNE SCIENCES INC FILES FOR MIXED SHELF OF UP TO $60 MILLION - SEC FILING Source text: [https://bit.ly/2AGhcqG] Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Alpine Immune Sciences Says Anticipate Having Enough Cash To Fund Planned Operations Into 2023

* ALPINE IMMUNE SCIENCES - ANTICIPATES HAVING ENOUGH CASH TO FUND PLANNED OPERATIONS INTO 2023, EXCLUDING REVENUE FROM EXISTING PARTNERSHIPS OR NEW ARRANGEMENTS

BRIEF-Alpine Immune Sciences And Abbvie Announce Option And License Agreement For Development And Commercialization Of ALPN-101

* ALPINE IMMUNE SCIENCES AND ABBVIE ANNOUNCE OPTION AND LICENSE AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALIZATION OF ALPN-101

BRIEF-Alpine Reports Qtrly Loss Per Share Of $0.30

* ALPINE IMMUNE SCIENCES REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE

BRIEF-Alpine Immune Sciences Says Q4 Loss Per Share Of $0.33

* ALPINE IMMUNE SCIENCES PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

BRIEF-Alpine Immune Sciences’ Alpn-101 Receives FDA Orphan Drug Designations For The Prevention And Treatment Of Acute Graft Versus Host Disease

* ALPINE IMMUNE SCIENCES’ ALPN-101 RECEIVES FDA ORPHAN DRUG DESIGNATIONS FOR THE PREVENTION AND TREATMENT OF ACUTE GRAFT VERSUS HOST DISEASE Source text for Eikon: Further company coverage:

Select another date: